BR112015023209A8 - novos medicamentos compreendendo uma composição de anticorpo enriquecida com uma carga principal de isoforma - Google Patents
novos medicamentos compreendendo uma composição de anticorpo enriquecida com uma carga principal de isoformaInfo
- Publication number
- BR112015023209A8 BR112015023209A8 BR112015023209A BR112015023209A BR112015023209A8 BR 112015023209 A8 BR112015023209 A8 BR 112015023209A8 BR 112015023209 A BR112015023209 A BR 112015023209A BR 112015023209 A BR112015023209 A BR 112015023209A BR 112015023209 A8 BR112015023209 A8 BR 112015023209A8
- Authority
- BR
- Brazil
- Prior art keywords
- antibody composition
- loading
- antibody
- enriched
- major isoform
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
Abstract
resumo da patente de invenã§ã£o para: ânovos medicamentos compreendendo uma composiãão de anticorpo enrriquecida com uma carga principal de isoformaâ. a presente invenã§ã£o situa-se no campo tã©cnico das terapias de anticorpos envolvendo um mecanismo de destruiã§ã£o pelo ccad. estã¡ relacionado a composiã§ãµes de anticorpos purificadas, obtidas pelo fracionamento cromatogrã¡fico de vã¡rias cargas de isoforma naturalmente presentes em uma composiã§ã£o de anticorpo e combinando uma ou mais fraã§ãµes cromatogrã¡ficas correspondendo ao pico predominante do cromatograma, a composiã§ã£o de anticorpo monoclonal resultante sendo enriquecida no dito pico predominante, o dito pico predominante representando pelo menos 85% do cromatograma da composiã§ã£o obtida, para uso como um medicamento.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR1352360A FR3003171B1 (fr) | 2013-03-15 | 2013-03-15 | Nouveaux medicaments comprenant une composition d'anticorps enrichie en isoforme de charge majoritaire |
PCT/EP2014/055179 WO2014140322A1 (fr) | 2013-03-15 | 2014-03-14 | Nouveaux médicaments comprenant une composition d'anticorps enrichie en isoforme de charge majoritaire |
Publications (2)
Publication Number | Publication Date |
---|---|
BR112015023209A2 BR112015023209A2 (pt) | 2017-07-18 |
BR112015023209A8 true BR112015023209A8 (pt) | 2018-01-23 |
Family
ID=48771615
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112015023209A BR112015023209A8 (pt) | 2013-03-15 | 2014-03-14 | novos medicamentos compreendendo uma composição de anticorpo enriquecida com uma carga principal de isoforma |
Country Status (11)
Country | Link |
---|---|
US (1) | US20160046722A1 (pt) |
EP (1) | EP2968533A1 (pt) |
JP (1) | JP2016512216A (pt) |
KR (1) | KR20150132522A (pt) |
CN (1) | CN105163758B (pt) |
AU (1) | AU2014230134A1 (pt) |
BR (1) | BR112015023209A8 (pt) |
CA (1) | CA2907358A1 (pt) |
FR (1) | FR3003171B1 (pt) |
MX (1) | MX2015012812A (pt) |
WO (1) | WO2014140322A1 (pt) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2729496B8 (en) | 2011-07-06 | 2017-10-18 | Genmab A/S | Modulation of complement-dependent cytotoxicity through modifications of the c-terminus of antibody heavy chains |
RU2744956C2 (ru) | 2016-05-04 | 2021-03-17 | Делаваль Холдинг Аб | Картридж для доильного сткана и доильный стакан |
FR3053688A1 (fr) * | 2016-07-06 | 2018-01-12 | Laboratoire Francais Du Fractionnement Et Des Biotechnologies | Mutants fc a activite fonctionnelle amelioree |
EP3498293A1 (en) | 2017-12-15 | 2019-06-19 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Treatment of monogenic diseases with an anti-cd45rc antibody |
EP3626265A1 (en) | 2018-09-21 | 2020-03-25 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Anti-human cd45rc antibodies and uses thereof |
MX2021008672A (es) | 2019-01-23 | 2021-11-03 | Encefa | Competidores de cd31 y usos de los mismos. |
CN113874720A (zh) * | 2019-05-23 | 2021-12-31 | 瑞泽恩制药公司 | 抗体结构域特异性电荷变异体的表征分析 |
WO2021057726A1 (zh) * | 2019-09-23 | 2021-04-01 | 南开大学 | 利用哺乳动物展示筛选FcγR特异性结合Fc |
CA3231944A1 (en) | 2021-09-16 | 2023-03-23 | Carole GUILLONNEAU | Anti-human cd45rc binding domains and uses thereof |
CN114236010A (zh) * | 2021-12-18 | 2022-03-25 | 苏州莱奥生物技术有限公司 | 一种生物活性药物的药代动力学分析方法 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HU230769B1 (hu) * | 1999-01-15 | 2018-03-28 | Genentech Inc. | Módosított effektor-funkciójú polipeptid-változatok |
FR2807767B1 (fr) * | 2000-04-12 | 2005-01-14 | Lab Francais Du Fractionnement | Anticorps monoclonaux anti-d |
FR2844513B1 (fr) * | 2002-09-13 | 2007-08-03 | Lab Francais Du Fractionnement | Anticorps pour adcc et induisant la production de cytokines. |
CA2499816C (en) * | 2002-09-27 | 2013-07-30 | Xencor, Inc. | Optimized fc variants and methods for their generation |
EA201492217A1 (ru) * | 2002-10-17 | 2015-06-30 | Генмаб А/С | Человеческие моноклональные антитела против cd20 |
EP2368578A1 (en) * | 2003-01-09 | 2011-09-28 | Macrogenics, Inc. | Identification and engineering of antibodies with variant Fc regions and methods of using same |
FR2861078B1 (fr) * | 2003-10-16 | 2007-09-21 | Lab Francais Du Fractionnement | NOUVELLES IgG3 UTILES POUR STIMULER LA PHAGOCYTOSE |
EA015584B1 (ru) * | 2005-03-23 | 2011-10-31 | Генмаб А/С | Антитело к cd38 человека и его применение |
EP2729496B8 (en) * | 2011-07-06 | 2017-10-18 | Genmab A/S | Modulation of complement-dependent cytotoxicity through modifications of the c-terminus of antibody heavy chains |
-
2013
- 2013-03-15 FR FR1352360A patent/FR3003171B1/fr not_active Expired - Fee Related
-
2014
- 2014-03-14 EP EP14709977.4A patent/EP2968533A1/fr not_active Withdrawn
- 2014-03-14 WO PCT/EP2014/055179 patent/WO2014140322A1/fr active Application Filing
- 2014-03-14 BR BR112015023209A patent/BR112015023209A8/pt not_active Application Discontinuation
- 2014-03-14 KR KR1020157029822A patent/KR20150132522A/ko not_active Application Discontinuation
- 2014-03-14 US US14/776,725 patent/US20160046722A1/en not_active Abandoned
- 2014-03-14 AU AU2014230134A patent/AU2014230134A1/en not_active Abandoned
- 2014-03-14 MX MX2015012812A patent/MX2015012812A/es unknown
- 2014-03-14 JP JP2015562236A patent/JP2016512216A/ja active Pending
- 2014-03-14 CA CA2907358A patent/CA2907358A1/fr not_active Abandoned
- 2014-03-14 CN CN201480024699.3A patent/CN105163758B/zh not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
FR3003171A1 (fr) | 2014-09-19 |
MX2015012812A (es) | 2016-05-09 |
US20160046722A1 (en) | 2016-02-18 |
JP2016512216A (ja) | 2016-04-25 |
KR20150132522A (ko) | 2015-11-25 |
CA2907358A1 (fr) | 2014-09-18 |
CN105163758A (zh) | 2015-12-16 |
BR112015023209A2 (pt) | 2017-07-18 |
CN105163758B (zh) | 2017-11-17 |
AU2014230134A1 (en) | 2015-10-29 |
WO2014140322A1 (fr) | 2014-09-18 |
EP2968533A1 (fr) | 2016-01-20 |
FR3003171B1 (fr) | 2015-04-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112015023209A8 (pt) | novos medicamentos compreendendo uma composição de anticorpo enriquecida com uma carga principal de isoforma | |
BR112019006194A2 (pt) | composições que compreendem um ligante de ligação ao receptor de canabinóides | |
BR112015023520A2 (pt) | purificação do conjugado de anticorpo-fármaco (adc) | |
EA201501032A1 (ru) | Фармацевтическая композиция, способы лечения и ее применения | |
BR112018011781A2 (pt) | molécula biespecífica possuindo um ou mais sítios de ligação a epítopo capazes de ligação imunoespecífica a (um) epítopo(s) de pd-1 e um ou mais sítios de ligação a epítopo capazes de ligação imunoespecífica a (um) epítopo(s) de ctla-4, e composição farmacêutica | |
BR112015027319A8 (pt) | Métodos e composições para modular a expressão de apolipoproteína (a) | |
BR112012001984B8 (pt) | anticorpos humanos com alta afinidade para angiopoietina-2 humana, uso dos mesmos e composição farmacêutica | |
BR112015021665A2 (pt) | misturas de isômeros de (metilciclohe-xil)tolueno, sua produção e uso na fabricação de plastificantes | |
BR112015011403A2 (pt) | uso de akkermansia para o tratamento de distúrbios metabólicos | |
BR112017016636A2 (pt) | formulação líquida estável para anticorpos monoclonais | |
BR112015019657A2 (pt) | composições tópicas e métodos de uso das mesmas | |
BR112015020050A2 (pt) | material óptico, composto para material óptico e sua utilização | |
BR112015027288A8 (pt) | uso de uma dose de imunossupressor, composição de nanocarreadores sintéticos tolerogênicos e kit | |
BR112014026740A2 (pt) | anticorpo, composição, métodos para tratar um mamífero e para fornecer um anticorpo com adcc realçada, e, uso de um anticorpo | |
BR112016001114A2 (pt) | membros da família tnf direcionados modificados | |
BR112018006368A2 (pt) | composição para desempenho melhorado | |
BR112014017716A8 (pt) | composições de ésteres de forbol, métodos para prevenir ou tratar acidente vascular cerebral e uso de ésteres de forbol | |
BR112012023660A2 (pt) | novos métodos para direcionar células-tronco cancerosas | |
BR112016001036A2 (pt) | fusocinas envolvendo citocinas com afinidades de ligação de receptores fortemente reduzida | |
BR112015004875A2 (pt) | formulações de anticorpo e seus usos | |
BR112015030543A2 (pt) | glicerol formador de película para aplicação tópica | |
BR112016001446A2 (pt) | Composições terapêuticas, produto de combinação, uso in vitro de flecainida e flecainida | |
BR112015030385A8 (pt) | composto, composto para uso e composição farmacêutica | |
BR112018070060A2 (pt) | composições para tratamento bucal com uma exibição de sabor eficiente | |
BR112016003584A8 (pt) | composições farmaceuticas e uso das mesmas para regressão de placa acelerada |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 6A ANUIDADE. |
|
B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |